Biology's Code Rewritten: A New Blueprint for Resilient Therapeutics

Professor Jason Chin has been awarded the 2026 Heinrich Wieland Prize for his pioneering work in expanding the genetic code, a breakthrough that allows for the systematic rewriting of biological rules. This recognition highlights the transition of synthetic biology from academic theory to an industrial-scale platform for therapeutic innovation through his company, Constructive Bio. By enabling the incorporation of non-natural amino acids into proteins, the technology provides a new blueprint for developing resilient medicines with enhanced properties and more sustainable manufacturing processes.

Professor Jason Chin’s receipt of the 250,000 EUR Heinrich Wieland Prize, bestowed by the Boehringer Ingelheim Stiftung, signals a major milestone for the synthetic biology sector. The award recognizes Chin’s success in engineering bacteria with a compressed genetic code, freeing up redundant codons to be reassigned to non-natural amino acids (ncAAs). This fundamental shift allows for the biosynthesis of proteins and polymers with properties not found in nature, such as enhanced stability and novel functions. Sir Greg Winter, Chair of Constructive Bio, likens this advancement to the advent of recombinant DNA technology, suggesting it will fundamentally transform the pharmaceutical industry's approach to drug discovery.

At the commercial level, Constructive Bio is leveraging this research through its proprietary Syn61 bacterial strain to move beyond traditional chemical synthesis. The platform enables the fermentation of products containing up to three different ncAAs at a multi-gram-per-litre scale, offering a more efficient and environmentally sustainable alternative to complex chemical processes. CEO Ola Wlodek emphasizes that what began as a scientific inquiry into the fixed rules of biology has now become a robust industrial capability for manufacturing therapeutics that were previously considered impossible to produce.

The most immediate application of this technology is the development of next-generation GLP-1 agonists for treating diabetes and obesity. Constructive Bio has already produced potent, DPPIV-resistant GLP-1 variants by incorporating ncAAs to improve stability and extend half-lives. This design-led approach allows scientists to move beyond the 20 canonical amino acids, providing a durable competitive advantage in creating optimized molecules. The platform’s ability to grow these complex peptides through fermentation represents a paradigm shift toward a more rational and scalable model for the future of the synthetic biology market.